Selecting a Treatment Regimen
Table 11. Hypoglycemic Agentsa (continued)
Generic (Brand)
Dose
TZDs (continued) Use restricted.
Rosiglitazone
(Avandia®)
Initial: 4 mg daily or
2 mg bid
Max: 8 mg daily or
4 mg bid
Rosiglitazone + metformin Initial: 2 mg/500 mg bid
(Avandamet®)
Max: 4 mg/1000 mg bid
Rosiglitazone +
glimepiride
(Avandaryl ®)
Max: 8 mg rosiglitazone and
4 mg glimepiride daily
Initial: 4 mg/1 mg or
4 mg/2 mg daily
a
Should not be used in patients with T1DM or for the treatment of diabetic ketoacidosis.
Dose adjustments should be made based on periodic HbA1c tests.
Titration to response within the dosing range will determine maintenance dose.
See specific product labeling for complete prescribing information including precautions and warnings.
Table 12. Pharmacokinetics of Human Insulin and Insulin
Analogs
Insulin
Generic (Brand)
Onset
Peak
Effective
Duration
Rapid-acting
Aspart injection (NovoLog®)
5-15 min
30-90 min
< 5 h
Lispro injection (Humalog®)
5-15 min
30-90 min
< 5 h
Glulisine injection (Apidra®)
Short-acting
Regular
Intermediate, basal
NPH
Long-acting, basal
Glargine injection (Lantus®)
5-15 min
30-90 min
< 5-8 h
30-60 min
2-3 h
5-8 h
2-4 h
4-10 h
10-16 h
2-4 h
"Flat"
20-24 h
Detemir injection (Levemir®)
Premixed
75% lispro protamine suspension
25% lispro injection
(Humalog® Mix 75/25™)
3-8 h
"Flat"
5.7-23.2 h
5-15 min
Broada
10-16 h
70% aspart protamine suspension
30% aspart injection
(NovoLog® Mix 70/30)
5-15 min
Broada
10-16 h
70% NPH/30% Regular
30-60 min
Broada
10-16 h
a
24
The biphasic insulins have a single broad skewed (asymmetric) peak.
